GRIN2A and DLG2

Number of citations of the paper that reports this interaction (PubMedID 10648730)
206

Data Source:
BioGRID (two hybrid)
HPRD (in vitro, in vivo)

		GRIN2A	DLG2
Description		glutamate ionotropic receptor NMDA type subunit 2A	discs large MAGUK scaffold protein 2
Image
GO Annotations	Cellular Component	Cell Endoplasmic Reticulum Plasma Membrane Integral Component Of Plasma Membrane Synaptic Vesicle Cell Surface Postsynaptic Density NMDA Selective Glutamate Receptor Complex Cell Junction Cytoplasmic Vesicle Membrane Presynaptic Membrane Dendritic Spine Postsynaptic Membrane Synaptic Membrane Postsynaptic Density Membrane Glutamatergic Synapse Integral Component Of Postsynaptic Density Membrane	Cytosol Plasma Membrane Voltage-gated Potassium Channel Complex Ionotropic Glutamate Receptor Complex Postsynaptic Density Membrane Basolateral Plasma Membrane Cell Junction Neuromuscular Junction Neuron Projection Perikaryon Juxtaparanode Region Of Axon Postsynaptic Density Membrane Glutamatergic Synapse Axon Cytoplasm
	Molecular Function	Amyloid-beta Binding NMDA Glutamate Receptor Activity Protein Binding Glutamate Receptor Activity Zinc Ion Binding Ligand-gated Ion Channel Activity Glutamate-gated Calcium Ion Channel Activity Signaling Receptor Activity Transmitter-gated Ion Channel Activity Involved In Regulation Of Postsynaptic Membrane Potential	Guanylate Kinase Activity Protein Binding Kinase Binding Structural Constituent Of Postsynaptic Density
	Biological Process	Startle Response Response To Amphetamine Glutamate Receptor Signaling Pathway Chemical Synaptic Transmission Brain Development Learning Or Memory Memory Visual Learning Response To Wounding Sensory Perception Of Pain Calcium-mediated Signaling Neurogenesis Sleep Directional Locomotion Ionotropic Glutamate Receptor Signaling Pathway Synaptic Transmission, Glutamatergic Negative Regulation Of Protein Catabolic Process Dopamine Metabolic Process Serotonin Metabolic Process Positive Regulation Of Apoptotic Process Response To Ethanol Regulation Of Synaptic Plasticity Modulation Of Chemical Synaptic Transmission Excitatory Postsynaptic Potential Long-term Synaptic Potentiation Activation Of Cysteine-type Endopeptidase Activity Calcium Ion Transmembrane Import Into Cytosol Excitatory Chemical Synaptic Transmission Protein Localization To Postsynaptic Membrane Cellular Response To Amyloid-beta Regulation Of NMDA Receptor Activity	MAPK Cascade Chemical Synaptic Transmission Embryo Development Negative Regulation Of Phosphatase Activity Sensory Perception Of Pain Cellular Response To Potassium Ion Receptor Clustering Establishment Or Maintenance Of Epithelial Cell Apical/basal Polarity GMP Metabolic Process GDP Metabolic Process Receptor Localization To Synapse Cell-cell Adhesion Maintenance Of Postsynaptic Density Structure Anterograde Axonal Protein Transport Retrograde Axonal Protein Transport Neurotransmitter Receptor Localization To Postsynaptic Specialization Membrane Regulation Of NMDA Receptor Activity
Pathways		Unblocking of NMDA receptors, glutamate binding and activation Unblocking of NMDA receptors, glutamate binding and activation Neurexins and neuroligins Synaptic adhesion-like molecules MECP2 regulates neuronal receptors and channels Assembly and cell surface presentation of NMDA receptors Assembly and cell surface presentation of NMDA receptors Negative regulation of NMDA receptor-mediated neuronal transmission Long-term potentiation	Unblocking of NMDA receptors, glutamate binding and activation Unblocking of NMDA receptors, glutamate binding and activation Ras activation upon Ca2+ influx through NMDA receptor RAF/MAP kinase cascade Neurexins and neuroligins Neurexins and neuroligins Assembly and cell surface presentation of NMDA receptors Negative regulation of NMDA receptor-mediated neuronal transmission Long-term potentiation
Drugs		Glutamic Acid Glycine Atomoxetine Pentobarbital Secobarbital Pethidine Acamprosate Felbamate Gabapentin Memantine Halothane Phenobarbital Tenocyclidine Prasterone Milnacipran Acetylcysteine Ketobemidone Gavestinel Magnesium acetate tetrahydrate Magnesium carbonate Fluciclovine (18F)
Diseases
GWAS		anorexia nervosa, attention-deficit/hyperactivity disorder, autism spectrum disorder, bipolar disorder, major depression, obsessive-compulsive disorder, schizophrenia, or Tourette syndrome (pleiotropy) ( 31835028) Autism spectrum disorder or schizophrenia ( 28540026) Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined) ( 23453885) Bipolar disorder ( 31043756) Bipolar I disorder ( 31043756) Chronic kidney disease ( 26420894) Cognitive ability, years of educational attainment or schizophrenia (pleiotropy) ( 31374203) Copper levels ( 26025379) FEV1 ( 30804560) General risk tolerance (MTAG) ( 30643258) Hepatitis B ( 22004137) Laryngeal squamous cell carcinoma ( 25194280) Lung function (FVC) ( 30804560) Metabolite levels ( 23823483) Night sleep phenotypes ( 27126917) Rosacea symptom severity ( 29771307) Schizophrenia ( 28991256 25056061 29483656 30285260) Tenofovir clearance in HIV infection ( 26148204) Thiazide-induced adverse metabolic effects in hypertensive patients ( 23400010) Waist circumference adjusted for BMI (smoking interaction) ( 28443625)	Age at first sexual intercourse ( 27089180) Attention function in attention deficit hyperactive disorder ( 26174813) BMI at adiposity rebound ( 31840077) Body fat mass ( 28552196) Body mass index ( 28552196) Cerebrospinal fluid t-tau:AB1-42 ratio ( 28641921) Chronic obstructive pulmonary disease ( 25584925) Chronic periodontitis ( 25008200) Familial squamous cell lung carcinoma ( 29924316) Height ( 28552196) Influenza A (H1N1) infection ( 26379185) Itch intensity from mosquito bite adjusted by bite size ( 28199695) Migraine without aura ( 28952330) Mild influenza (H1N1) infection ( 26379185) Modic changes ( 30808802) Myopia ( 27182965) Obesity-related traits ( 23251661) Pallidum volume ( 31530798) Parkinson's disease ( 25064009 28892059 28011712 17052657) Parkinson's disease or first degree relation to individual with Parkinson's disease ( 31701892) Phospholipid levels (plasma) ( 22359512) Post bronchodilator FEV1 ( 26634245) Post bronchodilator FEV1/FVC ratio ( 26634245) Protein quantitative trait loci ( 18464913) Putamen volume ( 29147026) Response to fenofibrate (triglyceride levels) ( 27002377) Response to TNF inhibitor in rheumatoid arthritis (change in swollen 28-joint count) ( 30166627) Schizophrenia ( 30285260) Spherical equivalent or myopia (age of diagnosis) ( 29808027) Subcortical brain region volumes ( 25607358) Trunk fat mass ( 28552196) Type 2 diabetes ( 31049640) Urate levels in overweight individuals ( 25811787) Weight ( 28552196) Wilms tumor ( 22544364)
Interacting Genes		28 interacting genes: ACTN1 AKT1 AP1M1 AP4M1 ARHGAP32 CAMK2A CAMK2B CASK CDK5 DLG1 DLG2 DLG3 DLG4 DLGAP1 FYN GRIN1 GRIN3A GRIN3B IL16 NEDD4 PATJ PLCG1 PRKCA PTK2B PTPN4 RGS3 SPTAN1 SRC	40 interacting genes: ABCA1 ATP2B2 ATP2B4 CACNG2 CNKSR2 CRIPT DLG1 DLG4 DLGAP1 ERBB4 FASLG FZD1 FZD4 FZD7 GLS2 GRID1 GRID2 GRIN1 GRIN2A GRIN2B GRIN2D GUCY1A2 KCNA4 KCNJ12 KCNJ2 KCNJ4 KHDRBS1 KIF1B LIN7A LRP2 MAP1A MAPK12 NLGN1 NLGN2 NLGN3 NOS1 SCN4A SCN5A SEMA4C WNT3A
Entrez ID		2903	1740
HPRD ID		00698	04663
Ensembl ID		ENSG00000183454	ENSG00000150672
Uniprot IDs		Q12879 Q547U9 Q59EW6	B7Z2T4 E9PN83 Q15700
PDB IDs		3NFL 5H8F 5H8H 5H8N 5H8Q 5I2K 5I2N 5KCJ 5KDT 5TP9 5TPA 6IRA 6IRF 6IRG 6IRH	2BYG 2HE2
Enriched GO Terms of Interacting Partners?
Tagcloud ?
Tagcloud (Difference) ?
Tagcloud (Intersection) ?